CN113543813A - Cd38特异性的双环肽配体 - Google Patents
Cd38特异性的双环肽配体 Download PDFInfo
- Publication number
- CN113543813A CN113543813A CN202080019655.7A CN202080019655A CN113543813A CN 113543813 A CN113543813 A CN 113543813A CN 202080019655 A CN202080019655 A CN 202080019655A CN 113543813 A CN113543813 A CN 113543813A
- Authority
- CN
- China
- Prior art keywords
- seq
- referred
- iii
- peptide
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 194
- 239000003446 ligand Substances 0.000 title claims abstract description 79
- 125000002619 bicyclic group Chemical group 0.000 title description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 239000012636 effector Substances 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 125000000524 functional group Chemical group 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 230000001404 mediated effect Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 38
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 36
- 125000000539 amino acid group Chemical group 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 22
- 239000002062 molecular scaffold Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- -1 1,3, 5-triazinan-1, 3, 5-triyl Chemical group 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 239000002254 cytotoxic agent Substances 0.000 claims description 9
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 24
- SZNGQSBRHFMZLT-IHRRRGAJSA-N Asn-Pro-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SZNGQSBRHFMZLT-IHRRRGAJSA-N 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- NGWIXHCFVSSVHX-IHPCNDPISA-N Cys-Tyr-Trp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NGWIXHCFVSSVHX-IHPCNDPISA-N 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 16
- 108010069495 cysteinyltyrosine Proteins 0.000 description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
- 239000000562 conjugate Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 10
- 238000011191 terminal modification Methods 0.000 description 10
- 239000004365 Protease Substances 0.000 description 9
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000001630 malic acid Substances 0.000 description 9
- 229940099690 malic acid Drugs 0.000 description 9
- 235000011090 malic acid Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 7
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229960002433 cysteine Drugs 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 5
- 108010069514 Cyclic Peptides Proteins 0.000 description 5
- 102000001189 Cyclic Peptides Human genes 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010042971 T-cell lymphoma Diseases 0.000 description 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 5
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 5
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000009277 hairy cell leukemia Diseases 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000009033 hematopoietic malignancy Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 150000003384 small molecules Chemical group 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- STLBOMUOQNIALW-BQBZGAKWSA-N Met-Gly-Cys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O STLBOMUOQNIALW-BQBZGAKWSA-N 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- BQASAMYRHNCKQE-IHRRRGAJSA-N Tyr-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N BQASAMYRHNCKQE-IHRRRGAJSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229960000448 lactic acid Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940032330 sulfuric acid Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 229940124295 CD38 monoclonal antibody Drugs 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- QRHWTCJBCLGYRB-FXQIFTODSA-N Met-Ala-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O QRHWTCJBCLGYRB-FXQIFTODSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- SVWQEIRZHHNBIO-WHFBIAKZSA-N Ser-Gly-Cys Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CS)C(O)=O SVWQEIRZHHNBIO-WHFBIAKZSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- QNTBGBCOEYNAPV-CWRNSKLLSA-N Trp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O QNTBGBCOEYNAPV-CWRNSKLLSA-N 0.000 description 2
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 2
- HGEHWFGAKHSIDY-SRVKXCTJSA-N Tyr-Asp-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O HGEHWFGAKHSIDY-SRVKXCTJSA-N 0.000 description 2
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001345 alkine derivatives Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 102000052645 human CD38 Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940045996 isethionic acid Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940099563 lactobionic acid Drugs 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229940074355 nitric acid Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FABVRSFEBCDJLC-UHFFFAOYSA-N 1,2,3-tris(bromomethyl)benzene Chemical compound BrCC1=CC=CC(CBr)=C1CBr FABVRSFEBCDJLC-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical class OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- YEELWQSXYBJVSV-UWJYBYFXSA-N Ala-Cys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YEELWQSXYBJVSV-UWJYBYFXSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004272 Benign hydatidiform mole Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 108091007381 CBL proteins Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- JXVFJOMFOLFPMP-KKUMJFAQSA-N Cys-Leu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JXVFJOMFOLFPMP-KKUMJFAQSA-N 0.000 description 1
- SDDJEOCJUFKAPV-BPUTZDHNSA-N Cys-Met-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CS)CCSC)C(O)=O)=CNC2=C1 SDDJEOCJUFKAPV-BPUTZDHNSA-N 0.000 description 1
- SRUKWJMBAALPQV-IHPCNDPISA-N Cys-Phe-Trp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SRUKWJMBAALPQV-IHPCNDPISA-N 0.000 description 1
- VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OONBGFHNQVSUBF-KBIXCLLPSA-N Ile-Gln-Cys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(O)=O OONBGFHNQVSUBF-KBIXCLLPSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 1
- UEXCHCYDPAIVDE-SRVKXCTJSA-N Phe-Asp-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UEXCHCYDPAIVDE-SRVKXCTJSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- GHXXDFDIDHIEIL-WFBYXXMGSA-N Trp-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N GHXXDFDIDHIEIL-WFBYXXMGSA-N 0.000 description 1
- NBHGNEJMBNQQKZ-UBHSHLNASA-N Trp-Asp-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N NBHGNEJMBNQQKZ-UBHSHLNASA-N 0.000 description 1
- IQIRAJGHFRVFEL-UBHSHLNASA-N Trp-Ser-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N IQIRAJGHFRVFEL-UBHSHLNASA-N 0.000 description 1
- QMNWABHLJOHGDS-IHRRRGAJSA-N Tyr-Met-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QMNWABHLJOHGDS-IHRRRGAJSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- UFVHVURXVBHPDA-UHFFFAOYSA-N n-(dichloromethyl)-n-ethylethanamine Chemical compound CCN(CC)C(Cl)Cl UFVHVURXVBHPDA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及与非芳香族分子支架共价结合以使得两个或多个肽环在与支架的附着点之间相对的多肽。具体地,本发明描述的是CD38的高亲和力结合剂的肽。本发明还包括药物缀合物、包含所述肽配体和药物缀合物的药物组合物,所述药物缀合物包含与一个或多个效应物和/或官能团缀合的所述肽,以及所述肽配体和药物缀合物在预防、抑制或治疗CD38介导的疾病或病症中的用途。
Description
技术领域
本发明涉及与非芳香族分子支架共价结合以使得两个或多个肽环在与支架的附着点之间相对的多肽。具体地,本发明描述的是CD38的高亲和力结合剂的肽。本发明还包括包含与一个或多个效应物和/或官能团缀合的所述肽的药物缀合物,包含所述肽配体和药物缀合物的药物组合物,以及所述肽配体和药物缀合物在预防、抑制或治疗CD38介导的疾病或病症中的用途。
背景技术
环肽能够以高亲和力和靶向特异性结合于蛋白靶标,因此是对于治疗学的发展有吸引力的分子类型。事实上,临床上已经成功使用了几种环肽,例如抗菌肽万古霉素、免疫抑制剂药物环孢菌素或抗癌药奥曲肽(Driggers等人(2008),Nat Rev Drug Discov 7(7),608-24)。良好的结合性质源于肽和靶标之间形成的相对大的相互作用表面以及环状结构的降低的构象柔性。典型地,大环结合于数百平方埃的表面,例如环肽CXCR4拮抗剂CVX15(Wu等人(2007),Science 330,1066-71),结合整联蛋白αVb3的具有Arg-Gly-Asp基序的环肽(Xiong等人(2002),Science 296(5565),151-5),或与尿激酶型纤溶酶原激活物结合的环肽抑制剂upain-1(Zhao等人(2007),J Struct Biol 160(1),1-10)。
由于其环状结构,肽大环比线性肽的柔韧性差,导致与靶标结合后熵损失较小,并导致更高的结合亲和力。与线性肽相比,降低的柔韧性还导致锁定靶标特异性构象,增加结合特异性。这种作用已经通过一种有效的和选择性基质金属蛋白酶8(MMP-8)的抑制剂来例证,当所述抑制剂的环被打开时其失去对其它MMP的选择性(Cherney等人(1998),J MedChem 41(11),1749-51)。通过大环化实现的有利的结合性质在具有多于一个肽环的多环肽(例如在万古霉素、乳链菌肽和放线菌素中)中更为显著。
不同的研究团队以前已经将具有半胱氨酸残基的多肽连接到合成分子结构上(Kemp和McNamara(1985),J.Org.Chem;Timmerman等人(2005),ChemBioChem)。Meloen及其同事已使用三(溴甲基)苯和相关分子将多个肽环快速定量地环化到合成的支架上,以结构模拟蛋白质表面(Timmerman等人(2005),ChemBioChem)。产生候选药物化合物的方法,其中通过将含半胱氨酸的多肽与分子支架(例如,1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA))连接,产生所述化合物(Heinis等人(2014)Angewandte Chemie,国际版53(6)1602-1606)。
已经开发了基于噬菌体展示的组合方法以产生并筛选出针对目的靶标的双环肽的大型文库(Heinis等人(2009),Nat Chem Biol 5(7),502-7和WO2009/098450)。简言之,在噬菌体上展示含有三个半胱氨酸残基和两个区域的六个随机氨基酸的线性肽(Cys-(Xaa)6-Cys-(Xaa)6-Cys)的组合文库,并通过将半胱氨酸侧链共价连接至小分子支架而环化。
发明内容
根据本发明的第一方面,提供一种CD38特异性的肽配体,其包含多肽和非芳香族分子支架,所述多肽含有被至少两个环序列隔开的至少三个半胱氨酸残基,以及所述非芳香族分子支架与所述多肽的半胱氨酸残基形成共价键,从而在所述分子支架上形成至少两个多肽环。
根据本发明的另一方面,提供了一种药物缀合物,其包含与一个或多个效应物和/或官能团缀合的如本文所限定的肽配体。
根据本发明的其它方面,提供一种药物组合物,其包含与一个或多个药学上可接受的赋形剂组合的如本文限定的肽配体或药物缀合物。
根据本发明的另一方面,提供了如本文所限定的肽配体或药物缀合物,其用于预防、抑制或治疗由CD38介导的疾病或病症的用途。
具体实施方式
在一个实施方案中,所述环序列包含2或7个氨基酸。
在另一个实施方案中,所述环序列包含被两个环序列隔开的三个半胱氨酸残基,所述两个环序列之一由2个氨基酸组成以及另一个由7个氨基酸组成。
在一个实施方案中,所述肽配体包含选自以下的氨基酸序列:
Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23);
或其药学上可接受的盐,其中X1-X5代表任何氨基酸残基、以及Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基。
在一个实施方案中,所述环序列包含被两个环序列隔开的三个半胱氨酸残基,所述两个环序列中的第一个由7个氨基酸组成,而所述两个环序列中的第二个由2个氨基酸组成,并且所述肽配体包含选自以下的氨基酸序列:
Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23);
或其药学上可接受的盐,其中X1-X6代表任何氨基酸残基,以及Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基。
在又一个实施方案中,Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23)的肽配体包括Ci-X1-W-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:24)的肽配体。
在又一个实施方案中,Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23)的肽配体包括选自SEQ ID NO:1-22中的任一个的氨基酸序列:
CiYWNPFMGCiiYTCiii(SEQ ID NO:1);
CiYWNPFTGCiiYSCiii(SEQ ID NO:2);
CiYWNPFIQCiiSPCiii(SEQ ID NO:3);
CiYWNPFTACiiYMCiii(SEQ ID NO:4);
CiYWNPFTACiiYTCiii(SEQ ID NO:5);
CiYWNPFAACiiYDCiii(SEQ ID NO:6);
CiYWNPFSGCiiYSCiii(SEQ ID NO:7);
CiMWNPFTGCiiYACiii(SEQ ID NO:8);
CiLYNPFTGCiiYDCiii(SEQ ID NO:9);
CiYWNPFSGCiiWDCiii(SEQ ID NO:10);
CiYWNPFMACiiFDCiii(SEQ ID NO:11);
CiYWNPFMGCiiYSCiii(SEQ ID NO:12);
CiYWNPFMACiiYVCiii(SEQ ID NO:13);
CiYWNPFMGCiiYVCiii(SEQ ID NO:14);
CiYWNPFTGCiiYACiii(SEQ ID NO:15);
CiYWNPFTACiiWSCiii(SEQ ID NO:16);
CiFWNPFTGCiiYSCiii(SEQ ID NO:17);
CiYWNPFTACiiFSCiii(SEQ ID NO:18);
CiYWNPFTACiiYVCiii(SEQ ID NO:19);
CiYWNPFTACiiYSCiii(SEQ ID NO:20);
CiYWNPFTACiiWACiii(SEQ ID NO:21);以及
CiYWNPFTACiiFACiii(SEQ ID NO:22),
或其药学上可接受的盐;其中Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基。
在又一个实施方案中,Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23)的肽配体包括选自以下的氨基酸序列:
A-(SEQ ID NO:1)-A(本文称为66-50-01-N001);
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:3)-A(本文称为66-50-03-N001);
A-(SEQ ID NO:4)-A(本文称为66-50-04-N001);
A-(SEQ ID NO:5)-A(本文称为66-50-05-N001);
A-(SEQ ID NO:6)-A(本文称为66-50-06-N001);
A-(SEQ ID NO:7)-A(本文称为66-50-07-N001);
A-(SEQ ID NO:8)-A(本文称为66-50-08-N001);
A-(SEQ ID NO:9)-A(本文称为66-50-09-N001);
A-(SEQ ID NO:10)-A(本文称为66-50-10-N001);
A-(SEQ ID NO:11)-A(本文称为66-50-11-N001);
A-(SEQ ID NO:12)-A(本文称为66-50-12-N001);
A-(SEQ ID NO:13)-A(本文称为66-50-13-N001);
A-(SEQ ID NO:14)-A(本文称为66-50-14-N001);
A-(SEQ ID NO:15)-DST(本文称为66-50-15-T01-N001);
A-(SEQ ID NO:15)-EAD(本文称为66-50-15-T02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:16)-DTS(本文称为66-50-22-T01-N001)。
ASDN-(SEQ ID NO:17)-A(本文称为66-50-17-T01-N001);
ARNE-(SEQ ID NO:17)-A(本文称为66-50-17-T02-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);
A-(SEQ ID NO:19)-DVP(本文称为66-50-19-T01-N001);
A-(SEQ ID NO:20)-TEN(本文称为66-50-19-T02-N001);
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001);
A-(SEQ ID NO:22)-EEP(本文称为66-50-21-T01-N001);以及
在一个实施方案中,分子支架选自1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA)以及所述肽配体包含选自以下的氨基酸序列:
A-(SEQ ID NO:1)-A(本文称为66-50-01-N001);
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:3)-A(本文称为66-50-03-N001);
A-(SEQ ID NO:4)-A(本文称为66-50-04-N001);
A-(SEQ ID NO:5)-A(本文称为66-50-05-N001);
A-(SEQ ID NO:6)-A(本文称为66-50-06-N001);
A-(SEQ ID NO:7)-A(本文称为66-50-07-N001);
A-(SEQ ID NO:8)-A(本文称为66-50-08-N001);
A-(SEQ ID NO:9)-A(本文称为66-50-09-N001);
A-(SEQ ID NO:10)-A(本文称为66-50-10-N001);
A-(SEQ ID NO:11)-A(本文称为66-50-11-N001);
A-(SEQ ID NO:12)-A(本文称为66-50-12-N001);
A-(SEQ ID NO:13)-A(本文称为66-50-13-N001);
A-(SEQ ID NO:14)-A(本文称为66-50-14-N001);
A-(SEQ ID NO:15)-DST(本文称为66-50-15-T01-N001);
A-(SEQ ID NO:15)-EAD(本文称为66-50-15-T02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:16)-DTS(本文称为66-50-22-T01-N001)。
ASDN-(SEQ ID NO:17)-A(本文称为66-50-17-T01-N001);
ARNE-(SEQ ID NO:17)-A(本文称为66-50-17-T02-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);
A-(SEQ ID NO:19)-DVP(本文称为66-50-19-T01-N001);
A-(SEQ ID NO:20)-TEN(本文称为66-50-19-T02-N001);
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001);
A-(SEQ ID NO:22)-EEP(本文称为66-50-21-T01-N001);以及
在又一个实施方案中,分子支架选自1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA),以及肽配体包含选自以下的氨基酸序列:
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);以及
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001)。
如本文中表1中所示,该实施方案的支架/肽配体显示出优异的CD38竞争性结合。
除非另外限定,否则本文中使用的所有技术和科学术语具有与本领域(如肽化学、细胞培养和噬菌体展示、核酸化学和生物化学领域)普通技术人员通常理解的含义相同的含义。将标准技术用于分子生物学、遗传和生化方法(参见Sambrook等人,MolecularCloning:A Laboratory Manual,第3版,2001,Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NY;Ausubel等人,Short Protocols in Molecular Biology(1999)第4版,John Wiley&Sons,Inc.),其并入本文以作参考。
命名法
编号
当提及本发明的肽内的氨基酸残基位置时,由于半胱氨酸残基(Ci、Cii和Ciii)是不变的,因而从编号中省略半胱氨酸残基,因此本发明的肽内的氨基酸残基的编号如下所指:
-Ci-Y1-W2-N3-P4-F5-M6-G7-Cii-Y8-T9-Ciii-(SEQ ID NO:1)。
为该说明书的目的,假定所有双环肽都与1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA)环化并生成三取代结构。与TATA的环化反应发生在Ci、Cii和Ciii上。
分子式
双环核心序列的N-或C-末端延伸区添加到序列的左侧或右侧,以连字符隔开。例如,N末端βAla-Sar10-Ala尾巴将表示为:
βAla-Sar10-A-(SEQ ID NO:X)。
反向肽序列
根据Nair等人(2003)J Immunol 170(3),1362-1373中的公开,设想本文公开的肽序列也将以其逆反形式使用。例如,该序列被颠倒(即,N末端变成C末端以及反之亦然),它们的立体化学也被颠倒(即,D-氨基酸变成L-氨基酸以及反之亦然)。
肽配体
如本文所指,肽配体是指与分子支架共价结合的肽。通常,这样的肽包含两个或多个能够与支架形成共价键的反应性基团(即,半胱氨酸残基),以及在所述反应性基团之间相对(subtended)的序列,因为肽与支架结合时该序列形成环,因而其被称为环序列。在当前情况下,肽包含至少三个半胱氨酸残基(在本文中称为Ci、Cii和Ciii),并在支架上形成至少两个环。
肽配体的优点
本发明的某些双环肽具有许多有利的性质,使得它们能够被认为是用于注射、吸入、鼻、眼、口或局部施用的合适的药物样分子。这些有利的特性包括:
-物种交叉反应性。这是临床前药效学和药代动力学评估的典型要求;
-蛋白酶稳定性。双环肽配体理想地应展示出对血浆蛋白酶、上皮(“膜锚定”)蛋白酶、胃和肠蛋白酶、肺表面蛋白酶、细胞内蛋白酶等的稳定性。应在不同物种之间保持蛋白酶稳定性,以便可以在动物模型中开发双环先导候选物,并有信心对人类施用;
-理想的溶解度曲线。这是带电荷的亲水残基与疏水残基的比例和分子内/分子间H键的函数,其对于配制和吸收目的是重要的;
-循环中的最佳血浆半衰期。根据临床适应症和治疗方案,可能需要在急性疾病管理环境中开发双环肽用于短期暴露,或开发在循环中具有增强保留的双环肽,从而对于更慢性的疾病状态的管理是最佳的。驱动想要的血浆半衰期的其它因素是为了最大治疗效率而要求持续暴露相对于由药剂持续暴露引起的伴随毒理学;以及
-选择性。本发明的某些肽配体与其它CD相比显示良好的选择性。
药学上可接受的盐
应当理解,盐形式属于本发明的范围内,并且提及肽配体时包括所述配体的盐形式。
可以通过常规化学方法,从包含碱性或酸性部分的母体化合物来合成本发明的盐,常规化学方法例如,在Pharmaceutical Salts:Properties,Selection,and Use,P.Heinrich Stahl(编)、Camille G.Wermuth(编)ISBN:3-90639-026-8,精装388页,2002年8月中描述的方法。通常,可以通过使这些化合物的游离酸或碱形式与水中、或在有机溶剂中、或在两者的混合物中适当的碱或酸进行反应,来制备这些盐。
可以用多种酸(无机和有机酸两者)形成酸加成盐(单盐或二盐)。酸加成盐的示例包括由选自以下的酸形成的单盐或二盐:乙酸、2,2-二氯乙酸、己二酸、藻酸、抗坏血酸(例如,L-抗坏血酸)、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、丁酸、(+)樟脑酸、樟脑磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环拉酸、十二烷基硫酸、乙烷-1,2-二磺酸、乙磺酸、2-羟基乙磺酸、甲酸、富马酸、半乳酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、葡萄糖醛酸(如,D-葡萄糖醛酸)、谷氨酸(如,L-谷氨酸)、α-氧代戊二酸、乙醇酸、马尿酸、氢卤酸(如氢溴酸、盐酸、氢碘酸)、羟乙基磺酸、乳酸(例如,(+)-L-乳酸、(±)-DL-乳酸)、乳糖酸、马来酸、苹果酸、(-)-L-苹果酸、丙二酸、(±)-DL-扁桃酸、甲磺酸、萘-2-磺酸、萘-1,5-二磺酸、1-羟基-2-萘甲酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、帕莫酸、磷酸、丙酸、丙酮酸、L-焦谷氨酸、水杨酸、4-氨基水杨酸、癸二酸、硬脂酸、琥珀酸、硫酸、丹宁酸、(+)-L-酒石酸、硫氰酸、对甲苯磺酸、十一烯酸和戊酸、以及酰化氨基酸和阳离子交换树脂。
一组具体的盐由以下形成的盐组成:乙酸、盐酸、氢碘酸、磷酸、硝酸、硫酸、柠檬酸、乳酸、琥珀酸、马来酸、苹果酸、羟乙基磺酸、富马酸、苯磺酸、甲苯磺酸、硫酸、甲磺酸(甲磺酸盐)、乙磺酸、萘磺酸、戊酸、丙酸、丁酸、丙二酸、葡萄糖醛酸和乳糖酸。一种具体的盐是盐酸盐。另一种具体的盐是乙酸盐。
如果化合物是阴离子化合物,或具有可以是阴离子的官能团(例如,-COOH可以是-COO-),则可以由有机或无机碱形成盐,产生合适的阳离子。合适的无机阳离子的示例包括但不限于碱金属离子,如Li+、Na+和K+;碱土金属阳离子,如Ca2+和Mg2+;和其它阳离子,例如Al3+或Zn+。合适的有机阳离子的示例包括但不限于铵离子(即NH4 +)和取代的铵离子(例如,NH3R+、NH2R2 +、NHR3 +、NR4 +)。一些合适的取代铵离子的示例是衍生自以下的那些:甲胺、乙胺、二乙胺、丙胺、二环己胺、三乙胺、丁胺、乙二胺、乙醇胺、二乙醇胺、哌嗪、苄胺、苯基苄胺、胆碱、葡甲胺和氨丁三醇,以及氨基酸,如赖氨酸和精氨酸。常见的季铵离子的示例是N(CH3)4 +。
当本发明的肽含有胺官能团时,这些可以形成季铵盐,例如通过根据本领域技术人员熟知的方法与烷化剂反应。这样的季铵化合物在本发明的肽的范围内。
修饰衍生物
应当理解,本文所限定的肽配体的修饰衍生物在本发明的范围内。此类合适的修饰衍生物的示例包括选自以下的一个或多个修饰:N-末端和/或C-末端修饰;用一个或多个非天然氨基酸残基替换一个或多个氨基酸残基(例如,用一个或多个等位或等电子氨基酸替换一个或多个极性氨基酸残基;用其它非天然等位或等电子氨基酸替换一个或多个非极性氨基酸残基);添加间隔基团;用一个或多个抗氧化性氨基酸残基替换一个或多个氧化敏感性氨基酸残基;用丙氨酸替换一个或多个氨基酸残基,用一个或多个D-氨基酸残基替换一个或多个L-氨基酸残基;双环肽配体内一个或多个酰胺键的N-烷基化;用替代性键替换一个或多个肽键;肽主链长修饰;用另一化学基团取代一个或多个氨基酸残基的α-碳上的氢,用合适的胺、硫醇、羧酸和酚反应性试剂修饰氨基酸(例如半胱氨酸、赖氨酸、谷氨酸/天冬氨酸和酪氨酸),以官能化所述氨基酸,和引入或替换带来适于官能化的正交反应性的氨基酸,例如带有叠氮基或炔基的氨基酸,其分别允许用带有炔或叠氮的部分进行官能化。
在一个实施方案中,修饰的衍生物包括N-末端和/或C-末端修饰。在另一实施方案中,其中所述修饰的衍生物包括使用合适的氨基反应化学的N-末端修饰,和/或使用合适的羧基反应化学的C-末端修饰。在另一实施方案中,所述N-末端或C-末端修饰包括添加效应物基团,所述效应物基团包括但不限于细胞毒性剂、放射螯合剂或发色团。
在另一实施方案中,修饰的衍生物包括N-末端修饰。在另一实施方案中,N-末端修饰包括N-末端乙酰基。在该实施方案中,在肽合成过程中,N-末端半胱氨酸基团(在本文中称为Ci的基团)被乙酸酐或其它合适的试剂封端,从而产生N-末端乙酰化的分子。该实施方案提供了去除氨基肽酶的潜在识别点的优点,避免了双环肽降解的可能性。
在一个可选的实施方案中,N-末端修饰包括添加分子间隔基团,其促进效应物基团的缀合并保留双环肽对其靶标的效力。
在另一个实施方案中,修饰的衍生物包括C-末端修饰。在另一个实施方案中,C-末端修饰包含酰胺基。在该实施方案中,C-末端半胱氨酸基团(本文中称为Ciii的基团)在肽合成过程中作为酰胺合成,从而产生C-末端被酰胺化的分子。该实施方案提供去除羧肽酶的潜在识别点的优点,降低了双环肽被蛋白水解降解的可能性。
在一个实施方案中,修饰的衍生物包括用一个或多个非天然氨基酸残基替换一个或多个氨基酸残基。在该实施方案中,可以选择具有等位/等电子侧链的非天然氨基酸,其既不被降解蛋白酶识别,也不对靶标效力产生任何不利影响。
可选择地,可以使用具有受约束的氨基酸侧链的非天然氨基酸,使得附近肽键的蛋白水解性水解在构象和空间上受到阻碍。具体地,这涉及脯氨酸类似物、庞大的侧链、Cα-二取代的衍生物(例如,氨基异丁酸,Aib)和环氨基酸,简单的衍生物是氨基-环丙基羧酸。
在一个实施方案中,修饰的衍生物包括添加间隔基团。在另一个实施方案中,修饰的衍生物包括向N-末端半胱氨酸(Ci)和/或C-末端半胱氨酸(Ciii)添加间隔基团。
在一个实施方案中,修饰的衍生物包括用一个或多个抗氧化性氨基酸残基替换一个或多个氧化敏感性氨基酸残基。在另一个实施方案中,修饰的衍生物包括用萘基丙氨酸或丙氨酸残基替换色氨酸残基。该实施方案提供改善所得双环肽配体的药物稳定性谱的优点。
在一个实施方案中,修饰的衍生物包括用一个或多个疏水氨基酸残基替换一个或多个带电荷的氨基酸残基。在可选择的实施方案中,修饰的衍生物包括用一个或多个带电荷的氨基酸残基替换一个或多个疏水性氨基酸残基。带电荷的氨基酸残基与疏水性氨基酸残基的正确平衡是双环肽配体的重要特征。例如,疏水性氨基酸残基影响血浆蛋白结合的程度,从而影响血浆中可利用的游离级分的浓度,而带电荷的氨基酸残基(尤其是精氨酸)可能会影响肽与细胞表面磷脂膜的相互作用。两者的组合可能影响肽药物的半衰期、分布体积和暴露,并且可以根据临床终点进行调整。另外,(如果肽药物已通过皮下施用)带电荷的氨基酸残基与疏水性氨基酸残基的正确组合和数量可以减少注射部位的刺激性。
在一个实施方案中,修饰的衍生物包括用一个或多个D-氨基酸残基替换一个或多个L-氨基酸残基。该实施方案被认为是通过空间位阻和通过D-氨基酸来稳定β-转角构象的倾向来增加蛋白水解稳定性(Tugyi等人(2005)PNAS,102(2),413–418)。
在一个实施方案中,修饰的衍生物包括去除任何氨基酸残基并用丙氨酸取代。该实施方案提供去除潜在的蛋白水解攻击位点的优点。
应当注意的是,每个上述提到的修饰都用于有意地改善肽的效力或稳定性。通过以下机制可以实现基于修饰的进一步效能改善:
-引入疏水部分,其利用疏水效应并降低解离速率,从而获得更高的亲和力;
-引入带电荷的基团,其利用长程离子相互作用,导致更快的速率和更高的亲和力(参见例如Schreiber等人,Rapid,electrostatically assisted association ofproteins(1996),Nature Struct.Biol.3,427-31);以及
-向肽中引入其它限制,例如,通过正确地限制氨基酸的侧链使得在靶标结合时熵的损失最小,限制骨架的扭转角使得在靶标结合时熵的损失最小,以及出于同样的原因在分子中引入其它环化。
(综述参见Gentilucci等人,Curr.Pharmaceutical Design,(2010),16,3185-203,和Nestor等人,Curr.Medicinal Chem(2009),16,4399-418)。
同位素变异
本发明包括所有药学上可接受的(放射性)同位素标记的本发明肽配体,其中一个或多个原子被具有相同原子序数但原子质量或质量数不同于通常在自然界中发现的原子质量或质量数的原子替换;本发明的肽配体其中附着的金属螯合基团(术语为“效应物”)能够保持相关的(放射性)同位素;以及本发明的肽配体,其中某些官能团被相关的(放射性)同位素或同位素标记的官能团共价替换。
适合包含在本发明的肽配体中的同位素的示例包括氢的同位素,如2H(D)和3H(T);碳,如11C、13C和14C;氯,如36Cl;氟,如18F;碘,如123I、125I和131I;氮,如13N和15N;氧,如15O、17O和18O;磷,如32P;硫,如35S;铜,如64Cu;镓,如67Ga或68Ga;钇,如90Y和镥,如177Lu;以及铋,如213Bi。
某些同位素标记的本发明肽配体,例如并入放射性同位素的那些,可用于药物和/或底物组织分布的研究中,并用于临床评估患病组织中CD38靶标的存在和/或不存在。本发明的肽配体还可具有有价值的诊断性质,在于它们可用于检测或鉴定标记化合物与其他分子、肽、蛋白质、酶或受体之间复合物的形成。检测或鉴定方法可以使用经标记试剂标记的化合物,标记试剂如放射性同位素、酶、荧光物质、发光物质(例如,鲁米诺、鲁米诺衍生物、荧光素、水母发光蛋白和荧光素酶)等。鉴于放射性同位素氚(即3H(T))和碳-14(即14C)易于引入且有现成的检测手段,其特别适用于此目的。
用较重的同位素如氘(即2H(D))取代,可以提供某些治疗优势,这是由于更高的代谢稳定性,例如体内半衰期延长或剂量需求降低,因此在某些情况下可能是优选的。
用正电子发射同位素(如11C、18F、15O和13N)取代可用于正电子发射断层扫描(PET)研究以检查靶标占有率。
通常可以通过本领域技术人员已知的常规技术或通过与所附实施例中描述的那些类似的方法,使用适当的同位素标记的试剂代替先前使用的未标记试剂来制备本发明的肽配体的同位素标记化合物。
非芳香族分子支架
本文提及的术语“非芳香族分子支架”是指本文限定的任何分子支架,其不包含芳香族(即不饱和)碳环或杂环系统。
非芳香族分子支架的合适示例描述于Heinis等人(2014)Angewandte Chemie,International Edition 53(6)1602-1606。
如前述文献所述,分子支架可以是小分子,例如有机小分子。
在一个实施方案中,分子支架可以是大分子。在一个实施方案中,分子支架是由氨基酸、核苷酸或碳水化合物组成的大分子。
在一个实施方案中,分子支架包含能够与多肽的官能团反应以形成共价键的反应性基团。
分子支架可以包含与肽形成连接的化学基团,例如胺、硫醇、醇、酮、醛、腈、羧酸、酯、烯烃、炔烃、叠氮化物、酸酐、琥珀酰亚胺、马来酰亚胺、烷基卤化物和酰基卤化物。
包含αβ不饱和羰基的化合物的示例是1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA)(Angewandte Chemie,国际版(2014),53(6),1602-1606)。
效应物和官能团
根据本发明的另一方面,提供了一种药物缀合物,其包含与一个或多个效应物和/或官能团缀合的如本文所限定的肽配体。
效应物和/或官能团可以连接到,例如多肽的N和/或C末端,或连接到多肽内的氨基酸、或连接到分子支架上。
适当的效应物基团包括抗体及其部分或片段。例如,效应物基团可包括抗体轻链恒定区(CL)、抗体CH1重链结构域、抗体CH2重链结构域、抗体CH3重链结构域、或其任意组合,除此之外,还有一个或多个恒定区结构域。效应物基团还可以包含抗体的铰链区(通常在IgG分子的CH1和CH2结构域之间发现这种区域)。
在本发明该方面的其它实施方案中,根据本发明的效应物基团是IgG分子的Fc区域。有利地,根据本发明的肽配体-效应物基团包含肽配体Fc融合体或由其组成,所述肽配体Fc融合体具有1天或更长、2天或更长、3天或更长、4天或更长、5天或更长、6天或更长、或7天或更长的tβ半衰期。最有利地,根据本发明的肽配体包含具有1天或更长的tβ半衰期的肽配体Fc融合体或由其组成。
官能团通常包括结合基团、药物、用于连接其它实体的反应基团、有助于将大环肽摄取到细胞中的官能团等。
肽穿透到细胞中的能力将使肽有效针对细胞内的靶标。可以被具有穿透到细胞中能力的肽所接近的靶标包括转录因子、细胞内信号转导分子(如酪氨酸激酶)和参与凋亡途径的分子。能够穿透细胞的官能团包括已经添加到肽或分子支架中的肽或化学基团。如衍生自VP22、HIV-Tat、果蝇的同源盒蛋白(触角蛋白)等的肽,例如,如Chen和Harrison,Biochemical Society Transactions(2007)第35卷,第4部分,第821页;Gupta等人,Advanced Drug Discovery Reviews(2004)第57卷9637所述。已显示有效通过质膜易位的短肽的示例包括来自果蝇触角蛋白的16个氨基酸的穿透肽(Derossi等人(1994)JBiol.Chem.第269卷,第10444页)、18个氨基酸的‘模型两亲性肽’(Oehlke等人(1998)Biochim Biophys Acts第1414卷,第127页)和HIV TAT蛋白的富含精氨酸的区域。非肽方法包括使用可以容易地附着于生物分子的小分子模拟物或SMOC(Okuyama等人(2007)NatureMethods第4卷第153页)。将胍基团添加到分子中的其它化学策略也增强细胞穿透(Elson-Scwab等人(2007)J Biol Chem第282卷,第13585页)。可以将小分子量分子(如类固醇)添加到分子支架中以增强细胞摄取。
可以与肽配体连接的一类官能团包括抗体及其结合片段,如Fab、Fv或单结构域片段。具体地,可以使用抗体,其与能够在体内增加肽配体半衰期的蛋白结合。
在一个实施方案中,根据本发明的肽配体-效应物基团具有选自以下的tβ半衰期:12小时或更长、24小时或更长、2天或更长、3天或更长、4天或更长、5天或更长、6天或更长、7天或更长、8天或更长、9天或更长、10天或更长、11天或更长、12天或更长、13天或更长、14天或更长、15天或更长或者20天或更长。有利地,根据本发明的肽配体-效应物基团或组合物将具有12至60小时的tβ半衰期。在其它实施方案中,其将具有一天或更长的tβ半衰期。在再其它的实施方案中,其将在12至26小时范围内。
在本发明的一个具体实施方案中,官能团选自金属螯合剂,其适于络合药学相关的金属放射性同位素。
可能的效应物基团还包括酶,例如用于酶/前药疗法的羧肽酶G2,其中肽配体替换ADEPT中的抗体。
在本发明的一个具体实施方案中,官能团选自药物,如用于癌症疗法的细胞毒性剂。合适的示例包括:烷化剂,如顺铂和卡铂、以及奥沙利铂、二氯甲基二乙胺、环磷酰胺、苯丁酸氮芥、异环磷酰胺;抗代谢剂包括嘌呤类似物硫唑嘌呤和巯嘌呤或嘧啶类似物;植物生物碱和萜类化合物包括长春花生物碱,如长春新碱、长春花碱、长春瑞滨和长春地辛;鬼臼毒素及其衍生物依托泊苷和替尼泊苷;紫杉类,包括紫杉醇,最初称为Taxol;拓扑异构酶抑制剂包括喜树碱:伊立替康和拓扑替康,以及II型抑制剂,包括安吖啶、依托泊苷、磷酸依托泊苷和替尼泊苷。其它药剂可包括抗肿瘤抗生素,其包括免疫抑制剂放线菌素D(用于肾移植)、多柔比星、表柔比星、博来霉素、刺孢霉素等。
在根据本发明的另一具体实施方案中,细胞毒性剂选自美登素生物碱(例如,DM1)或单甲基澳瑞他汀(例如,MMAE)。
DM1是细胞毒性剂,其是美登素的含巯基衍生物,具有以下结构:
单甲基澳瑞他汀E(MMAE)是合成的抗肿瘤剂,具有以下结构:
在一个实施方案中,细胞毒性剂通过可切割的键(如二硫键或蛋白酶敏感的键)与双环肽连接。在其它实施方案中,修饰与二硫键相邻的基团以控制二硫键的位阻(hindrance),并由此控制细胞毒性剂的切割和伴随释放的速率。
已发表的文献建立通过在二硫键的任一侧引入空间位阻来修饰二硫键对还原的易感性的可能性(Kellogg等人(2011)Bioconjugate Chemistry,22,717)。更大程度的空间位阻减少细胞内谷胱甘肽还有细胞外(全身)还原剂的还原速率,从而减少细胞内外由此释放毒素的难易程度。因此,通过仔细选择二硫键任一侧的位阻程度,可以实现循环中二硫化物稳定性的最佳选择(使得毒素的不期望副作用最小化)与细胞内环境中的有效释放(使得治疗效果最大化)。
通过在分子构建体的靶向实体(此处,双环肽)或毒素侧引入一个或多个甲基来调节二硫键任一侧的位阻。
在一个实施方案中,细胞毒性剂和接头选自WO 2016/067035(其中的细胞毒性剂和接头通过引用并入本文)中描述的那些的任意组合。
合成
本发明的肽可以通过标准技术合成制备,然后与分子支架在体外反应。进行此操作时,可以使用标准化学方法。这样可以快速大规模地制备可溶性材料,以用于进一步的下游实验或验证。使用诸如在Timmerman等人(同上)中公开的常规化学来完成这样的方法。
因此,本发明还涉及如本文所述选择的多肽或缀合物的制备,其中所述制备任选地包括如下所述的其它步骤。在一个实施方案中,这些步骤在通过化学合成制备的最终产物多肽/缀合物上进行。
当制备缀合物或复合物时,可任选取代目的多肽中的氨基酸残基。
肽也可以延伸,以并入例如另一个环并因此引入多种特异性。
为了延伸肽,可以使用标准固相或溶液相化学法,使用正交保护的赖氨酸(和类似物),简单地在其N-末端或C-末端或在环内化学延伸。可以使用标准(生物)缀合技术来引入活化的或可活化的N-或C-末端。可选择地,可以通过片段缩合或天然化学连接添加,例如,如(Dawson等人,1994Synthesis of Proteins by Native Chemical Ligation.Science266:776-779)所述,或者通过酶进行添加,例如,使用如(Chang等人Proc Natl Acad Sci US A.1994,12月20;91(26):12544-8或Hikari等人,Bioorganic&Medicinal ChemistryLetters第18卷,第22期,2008年11月15日,第6000-6003页)所述的变位酶。
可选择地,可以通过二硫键的进一步缀合来延伸或修饰肽。这具有一旦处于细胞还原环境中时允许第一和第二肽彼此分离的其它优点。在这种情况下,可以在第一肽的化学合成期间加入分子支架,以使得与三个半胱氨酸基团反应;然后可以将另外的半胱氨酸或硫醇附加到第一肽的N或C末端,使得该半胱氨酸或硫醇仅与第二肽的游离半胱氨酸或硫醇反应,形成二硫键连接的双环肽-肽缀合物。
类似的技术同样适用于两个双环和双特异性大环的合成/偶联,潜在地产生四特异性分子。
此外,可以以相同的方式,使用适当的化学方法,在N-或C-末端或通过侧链的偶联来完成添加其它官能团或效应物基团。在一个实施方案中,以不阻断任一实体活性的方式进行偶联。
药物组合物
根据本发明的另一方面,提供一种药物组合物,其包含与一个或多个药学上可接受的赋形剂的组合的本文所限定的肽配体和药物缀合物。
一般地,本发明的肽配体将与药理学上适当的赋形剂或载体一起以纯化的形式使用。通常,这些赋形剂或载体包括水溶液或醇/水溶液、乳液或悬浮液,包括盐和/或缓冲的介质。肠胃外载剂包括氯化钠溶液、林格氏右旋糖、右旋糖和氯化钠以及乳酸林格氏液。合适的生理学上可接受的佐剂(如果需要将多肽复合物保持在悬浮液中)可选自增稠剂,如羧甲基纤维素、聚乙烯吡咯烷酮、明胶和藻酸盐。
静脉内运载体包括液体和营养补充剂和电解质补充剂,如基于林格氏右旋糖的那些。还可以存在防腐剂和其它添加剂,例如抗微生物剂、抗氧化剂、螯合剂和惰性气体(Mack(1982)Remington's Pharmaceutical Sciences,第16版)。
本发明的肽配体可以用作单独施用的组合物,或者与其它试剂联合施用。这些可包括抗体、抗体片段和各种免疫治疗药物,如环孢菌素、甲氨蝶呤、阿霉素或顺铂以及免疫毒素。药物组合物可以包括以下的“混合物”:各种细胞毒性剂或其它试剂联合本发明的蛋白配体,或甚至具有不同特异性的根据本发明的所选多肽的组合(如使用不同的靶配体所选择的多肽),无论它们是否在施用前合并。
根据本发明的药物组合物的施用途径可以是本领域普通技术人员公知的任何一种。对于治疗,可以根据标准技术将本发明的肽配体施用至任何患者。施用可以通过任何适当的方式进行,包括肠胃外、静脉内、肌内、腹膜内、经皮、通过肺部途径、或者还可以适当地通过用导管直接输注。优选地,根据本发明的药物组合物通过吸入施用。施用的剂量和频率将取决于患者的年龄、性别和病状、其它药物的同时施用、禁忌症(counter-indication)和临床医生应考虑的其它参数。
可以冻干本发明的肽配体用于储存,并在使用前在合适的载体中重构。已经证明该技术是有效的,并且可以采用本领域已知的冻干和重构技术。本领域技术人员将理解,冻干和重构可导致不同程度的活性损失,并且可能必须向上调整水平以进行补偿。
可以施用含有本发明肽配体或其混合物的组合物用于预防性和/或治疗性处理。在某些治疗应用中,将实现所选细胞群的至少部分抑制、压制、调节、杀伤或一些其它可衡量参数的足够量限定为“治疗有效剂量”。实现该剂量所需的量将取决于疾病的严重程度和患者自身免疫系统的一般状态,但通常范围为每千克体重0.005至5.0mg所选的肽配体,更通常使用的剂量为0.05至2.0mg/kg/剂量。对于预防性应用,含有本发明肽配体或其混合物的组合物也可以相似或稍低的剂量施用。
含有根据本发明的肽配体的组合物可用于预防和治疗环境,以帮助改变、灭活、杀伤或去除哺乳动物中选择的靶细胞群。此外,本文所述的肽配体可以选择性用于在离体或体外以用于从细胞的异质集合物中杀伤、损耗或以其它方式有效除去靶细胞群。来自哺乳动物的血液可以与选择的肽配体离体组合,由此从血液中杀伤或以其它方式除去不想要的细胞,并根据标准技术将血液返回到哺乳动物中。
治疗用途
本发明的双环肽具有作为CD38结合剂的特定作用。
CD38是45kD的II型跨膜糖蛋白,具有长的C末端胞外结构域和短的N末端胞质结构域。CD38蛋白是一种双功能胞外酶,其可催化NAD+转化为环状ADP-核糖(cADPR),也可将cADPR水解为ADP-核糖。在个体发生过程中,CD38出现在CD34+定向干细胞和淋巴、红细胞和髓细胞的谱系定向祖细胞上。CD38表达主要在淋巴谱系中持续存在,在T和B细胞发育的不同阶段具有不同的表达水平。
CD38在许多造血恶性肿瘤和源自各种造血恶性肿瘤的细胞系中上调,所述造血恶性肿瘤包括非霍奇金淋巴瘤(NHL)、伯基特淋巴瘤(BL)、多发性骨髓瘤(MM)、B慢性淋巴细胞白血病(B-CLL)、B和T急性淋巴细胞白血病(ALL)、T细胞淋巴瘤(TCL)、急性髓系白血病(AML)、毛细胞白血病(HCL)、霍奇金淋巴瘤(HL)和慢性髓系白血病(CML)。另一方面,造血系统的大多数原始多能干细胞是CD38-。在造血恶性肿瘤中CD38表达及其与疾病进展的相关性使CD38成为抗体治疗的一个有吸引力的靶标。
据报道CD38参与Ca2+动员(Morra等人(1998)FASEB J.12;581-592;Zilber等人(2000)Proc Natl Acad Sci USA 97,2840-2845)以及在淋巴和髓细胞或细胞系中,通过多种信号分子的酪氨酸磷酸化进行信号转导,包括磷脂酶C-γ、ZAP-70、syk和c-cbl(Funaro等人(1993)Eur J Immunol 23,2407-2411;Morra等人(1998),同上;Funaro等人(1990)JImmunol 145,2390-2396;Zubiaur等人(1997)J Immunol 159,193-205;Deaglio等人(2003)Blood 102,2146-2155;Todisco等人(2000)Blood 95,535-542;Konopleva等人(1998)J Immunol 161,4702-4708;Zilber等人(2000)Proc Natl Acad Sci USA 97,2840-2845;Kitanaka等人(1997)J Immunol 159,184-192;Kitanaka等人(1999)J Immunol 162,1952-1958;Mallone等人(2001)Int Immunol 13,397-409)。基于这些观察,CD38被认为是淋巴和髓细胞在正常发育过程中成熟和活化的重要信号转导分子。
CD38在信号转导和造血作用中的确切作用仍不清楚,特别是因为大多数这些信号转导研究中使用异位过表达CD38的细胞系和抗CD38单克隆抗体,CD38和抗CD38单克隆抗体是非生理配体。因为CD38蛋白具有产生cADPR的酶活性,其是可诱导Ca2+动员的分子(Lee等人(1989)J Biol Chem 264,1608-1615;Lee和Aarhus(1991)Cell Regul 2,203-209),据提议单克隆抗体的CD38连接通过增加cADPR的产生来触发淋巴细胞中的Ca2+动员和信号转导(Lee等人(1997)Adv Exp Med Biol 419,411-419)。与该假设相反,CD38蛋白的截断和点突变分析显示,其胞质尾部和其酶活性对于抗CD38抗体介导的信号转导均不是必需的(Kitanaka等人(1999)J Immunol 162,1952-1958;Lund等人(1999)J Immunol 162,2693-2702;Hoshino等人(1997)J Immunol 158,741-747)。
CD38功能的最佳证据来自CD38-/-基因敲除小鼠,所述小鼠由于树突状细胞迁移缺陷在其先天免疫中具有缺陷以及降低的T细胞依赖性体液反应(Partida-Sanchez等人,(2004)Immunity 20,279-291;Partida-Sanchez等人(2001)Nat Med 7,1209-1216)。尽管如此,尚不清楚小鼠的CD38功能是否与人类相同,因为造血作用中的CD38表达模式在人和小鼠之间存在很大差异:a)与人类未成熟的祖干细胞不同,小鼠中类似的祖干细胞表达高水平的CD38(Randall等人(1996)Blood 87,4057-4067;Dagher等人(1998)Biol BloodMarrow Transplant 4,69-74),b)而在人类B细胞发育过程中,在生发中心B细胞和浆细胞中发现高水平的CD38表达(Uckun(1990)Blood 76,1908-1923;Kumagai等人(1995)J ExpMed 181,1101-1110),在小鼠中,在相应细胞中CD38表达水平低(Oliver等人(1997)JImmunol 158,1108-1115;Ridderstad和Tarlinton(1998)J Immunol 160,4688-4695)。
在文献中已经描述了几种对各种肿瘤细胞和细胞系具有不同增殖特性的抗人CD38抗体。例如,在来自MM患者或正常个体的外周血单核效应细胞存在的情况下,具有小鼠Fab和人IgG1 Fc的嵌合OKT10抗体,可非常有效地针对淋巴细胞介导抗体依赖的细胞介导的细胞毒性(ADCC)(Stevenson等人(1991)Blood 77,1071-1079)。抗CD38抗体AT13/5的CDR嫁接人源化版本已证明对CD38阳性细胞系具有有效的ADCC活性(美国专利申请号09/797,941)。人单克隆抗CD38抗体已证明通过ADCC和/或补体依赖的细胞毒性(CDC)介导的CD38阳性细胞系的体外杀伤,并推迟携带MM细胞系RPMI-8226的SCID小鼠中的肿瘤生长(WO 2005/103083)。另一方面,几种抗CD38抗体(IB4、SUN-4B7和OKT10,而不是IB6、AT1或AT2)诱导来自正常个体的外周血单核细胞(PBMC)的增殖(Ausiello等人(2000)Tissue Antigens 56,539-547)。
现有技术的一些抗体已经证明能够在CD38+B细胞中触发凋亡。然而,它们只能在基质细胞或源自基质的细胞因子存在的情况下这样做。据报道,一种激动性抗CD38抗体(IB4)可防止人生发中心(GC)B细胞的凋亡(Zupo等人,(1994)Eur J Immunol 24,1218-1222),并诱导KG-1和HL-60AML细胞的增殖(Konopleva等人(1998)J Immunol 161,4702-4708),但在Jurkat T成淋巴细胞的细胞中诱导凋亡(Morra等人(1998)FASEB J 12,581-592)。另一种抗CD38抗体T16诱导来自ALL患者的未成熟淋巴细胞和白血病成淋巴细胞的凋亡(Kumagai等人,(1995)J Exp Med 181,1101-1110),以及来自AML患者的白血病成髓细胞的凋亡(Todisco等人(2000)Blood 95,535-542),但T16仅在基质细胞或源自基质的细胞因子(IL-7、IL-3、干细胞因子)存在下诱导凋亡。
根据本发明的方法选择的多肽配体可用于体内治疗和预防应用、体外和体内诊断应用、体外测定和试剂应用等。具有选择的特异性水平的配体可用在以下应用中,涉及在需要交叉反应的非人动物中进行测试,或者在需要小心控制与同源物或旁系同源物的交叉反应的诊断应用中。在一些应用中,例如疫苗应用,可以利用对预定范围的抗原引起免疫应答的能力调整针对特定疾病和病原体的疫苗。
对于哺乳动物施用,优选具有至少90至95%同质性的基本上纯的肽配体,并且对于药物施用(尤其是当哺乳动物是人时),最优选98至99%或更高的同质性。经过纯化、部分纯化、或至所需的同质性后,所选择的多肽可以用于诊断或治疗(包括离体)、或用于开发和执行测定程序、免疫荧光染色等(Lefkovite和Pernis,(1979和1981年),ImmunologicalMethods,卷I和II,Academic Press,NY)。
根据本发明的另一个方面,提供了如本文所限定的肽配体或药物缀合物,其用于预防、抑制或治疗由CD38介导的疾病或病症。
根据本发明的另一个方面,提供了一种预防、抑制或治疗由CD38介导的疾病或病症的方法,该方法包括向需要其的患者施用本文所限定的肽配体的效应物基团和药物缀合物。
在一个实施方案中,CD38是哺乳动物CD38。在另一个实施方案中,哺乳动物CD38是人CD38(hCD38)。
在一个实施方案中,由CD38介导的疾病或病症选自癌症。
可以治疗(或抑制)的癌症(及其良性对应物)的示例包括但不限于上皮起源的肿瘤(各种类型的腺瘤和癌,包括腺癌、鳞状癌、移行细胞癌和其他癌),例如膀胱癌和泌尿道癌、乳腺癌、胃肠道癌(包括食管、胃(胃部的)、小肠、结肠、直肠和肛门)、肝癌(肝细胞癌)、胆囊和胆道系统癌、外分泌胰腺癌、肾癌、肺癌(例如腺癌、小细胞肺癌、非小细胞肺癌、细支气管肺泡癌和间皮瘤)、头颈部癌(例如舌癌、口腔癌、喉癌、咽癌、鼻咽癌、扁桃体癌、唾液腺癌、鼻腔癌和鼻旁窦癌)、卵巢癌、输卵管癌、腹膜癌、阴道癌、外阴癌、阴茎癌、子宫颈癌、子宫肌层癌、子宫内膜癌、甲状腺癌(例如甲状腺滤泡癌)、肾上腺癌、前列腺癌、皮肤和附属物癌(例如黑素瘤、基底细胞癌、鳞状细胞癌、角化棘皮瘤、发育异常痣);血液学恶性肿瘤(即白血病、淋巴瘤)和恶变前血液病和边缘恶性肿瘤的疾病包括血液学恶性肿瘤和淋巴系统的相关病症(例如,急性淋巴细胞白血病[ALL]、慢性淋巴细胞性白血病[CLL]、B-细胞淋巴瘤如弥漫大B细胞淋巴瘤[DLBCL]、滤泡性淋巴瘤、伯基特淋巴瘤、套细胞淋巴瘤、T细胞淋巴瘤和白血病、自然杀伤[NK]细胞淋巴瘤、霍奇金氏淋巴瘤、毛细胞白血病、意义未明的单克隆丙种球蛋白血症、浆细胞瘤、多发性骨髓瘤和移植后淋巴细胞增生性疾病),以及血液学恶性肿瘤和骨髓系相关病症(例如,急性髓性白血病[AML]、慢性髓性白血病[CML]、慢性髓性单核细胞白血病[CMML]、嗜酸性粒细胞增多综合征、骨髓增生性疾病如真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化、骨髓增生综合征、骨髓增生异常综合征和早幼粒细胞性白血病);间叶细胞源的肿瘤,例如软组织、骨或软骨的肉瘤如骨肉瘤、纤维肉瘤、软骨肉瘤、横纹肌肉瘤、平滑肌肉瘤、脂肪肉瘤、血管肉瘤、卡波西肉瘤、尤因氏肉瘤、滑膜肉瘤、上皮样肉瘤、胃肠道间质瘤、良性和恶性组织细胞瘤、和隆突性皮肤纤维肉瘤;中枢或周围神经系统的肿瘤(例如星形细胞瘤、神经胶质瘤和成胶质细胞瘤、脑膜瘤、室管膜瘤、松果体瘤和神经鞘瘤);内分泌肿瘤(例如垂体肿瘤、肾上腺肿瘤、胰岛细胞肿瘤、甲状旁腺肿瘤、类癌瘤和甲状腺髓样癌);眼和附属器肿瘤(例如成视网膜细胞瘤);生殖细胞和滋养细胞肿瘤(例如畸胎瘤、精原细胞瘤、无性细胞瘤、葡萄胎和绒毛膜癌);以及儿科和胚胎肿瘤(例如成神经管细胞瘤、成神经细胞瘤、维尔姆斯瘤和原始神经外胚层肿瘤);或先天性或其他的综合症,其使患者易患恶性肿瘤(例如着色性干皮症)。
在另一实施方案中,所述癌症选自造血恶性肿瘤、例如选自:非霍奇金淋巴瘤(NHL)、伯基特淋巴瘤(BL)、多发性骨髓瘤(MM)、B慢性淋巴细胞性白血病(B-CLL)、B和T急性淋巴细胞性白血病(ALL)、T细胞淋巴瘤(TCL)、急性髓性白血病(AML)、毛细胞白血病(HCL)、霍奇金淋巴瘤(HL)、和慢性粒细胞白血病(CML)。
本文中对术语“预防”的引用涉及在诱发疾病之前施用保护性组合物。“抑制”是指在诱发事件之后但在疾病的临床表现之前施用组合物。“治疗”涉及在疾病症状变得明显之后施用保护性组合物。
可获得可用于筛选肽配体在保护免于疾病或治疗疾病中的有效性的动物模型系统。本发明促进动物模型系统的使用,其使得可以开发可与人和动物靶标交叉反应的多肽配体,以允许使用动物模型。
参考以下实施例进一步描述本发明。
实施例
材料和方法
肽合成
使用由Peptide Instruments制造的Symphony肽合成仪和MultiSynTech制造的Syro II合成仪,基于Fmoc化学法进行肽合成。使用标准的Fmoc-氨基酸(Sigma,Merck),带有适当的侧链保护基团:在每种情况下使用适用的标准偶联条件,然后使用标准方法进行脱保护。使用HPLC纯化肽,在分离后用1,3,5-三丙烯酰基六氢-1,3,5-三嗪(TATA,Sigma)进行修饰。为此,将线性肽用50:50MeCN:H2O稀释至约35mL,加入约500μL的100mM TATA的乙腈溶液,并用5mL的1M NH4HCO3的H2O溶液引发反应。使反应在室温下进行约30-60分钟,并且反应完成就立即冻干(通过MALDI判断)。完成后,将1ml的1M L-半胱氨酸盐酸盐一水合物(Sigma)的H2O溶液加入反应,在室温下持续约60分钟,以淬灭任何过量的TATA。
冻干后,如上纯化修饰的肽,同时用Gemini C18柱(Phenomenex)替换Luna C8,并将酸更改为0.1%三氟乙酸。合并含有正确TATA-修饰物质的纯级分,冻干并在-20℃进行储存。
除非另有说明,所有氨基酸均以L-构型使用。
在某些情况下,先将肽转化为活化的二硫化物再使用以下方法与毒素的游离硫醇基偶联;将4-甲基(琥珀酰亚胺基4-(2-吡啶硫代)戊酸酯)(100mM)在干燥DMSO(1.25mol当量)中的溶液加入到肽(20mM)在干燥DMSO(1mol当量)中的溶液中。将反应物充分混合并加入DIPEA(20mol当量)。通过LC/MS监测反应直至完成。
生物数据
1.CD38竞争性结合测定法
使用与Lea等人(Expert Opin Drug Discov.2011 6(1):17–3)中所报道的方法,使用荧光偏振测定法确定本发明的肽对人CD38的亲和力(Ki),以及当Fl是荧光素分子时,使用以下荧光标记的肽ACYWNPFTGCYTCA-Sar6-K(Fl)((SEQ ID NO:25)-Sar6-K(Fl))用于TATA衍生物。
在上述CD38竞争结合测定法中检测本发明的肽配体,结果如表1所示:
表1:本发明的肽配体的生物测定数据
肽 | 分子支架 | Ki(nM) |
66-50-01-N001 | TATA | 393±141.12 |
66-50-02-N001 | TATA | 97.8±22.67 |
66-50-03-N001 | TATA | 1703±872.18 |
66-50-04-N001 | TATA | 811.5±187.18 |
66-50-05-N001 | TATA | 438±192.08 |
66-50-06-N001 | TATA | 935n=1 |
66-50-07-N001 | TATA | 497.5±198.94 |
66-50-08-N001 | TATA | 158±68.24 |
66-50-09-N001 | TATA | 749±64.68 |
66-50-10-N001 | TATA | 335±56.84 |
66-50-11-N001 | TATA | 684.5±157.78 |
66-50-12-N001 | TATA | 315±362.59 |
66-50-13-N001 | TATA | 784.5±87.22 |
66-50-14-N001 | TATA | 939.5±285.17 |
66-50-15-T01-N001 | TATA | 104±90.16 |
66-50-15-T02-N001 | TATA | 179±125.44 |
66-50-16-T01-N001 | TATA | 90±49 |
66-50-17-T01-N001 | TATA | 358.5±187.18 |
66-50-17-T02-N001 | TATA | 260±160.72 |
66-50-18-T01-N001 | TATA | 77.5±51.94 |
66-50-19-T001-N001 | TATA | 575±219.52 |
66-50-19-T002-N001 | TATA | 315.5±4.9 |
66-50-20-T001-N001 | TATA | 85±115.64 |
66-50-21-T001-N001 | TATA | 337±229.32 |
66-50-22-T001-N001 | TATA | 182.5±46.06 |
序列表
<110> 拜斯科技术开发有限公司
<120> CD38特异性的双环肽配体
<130> BIC-C-P2515PCT
<150> GB1900529.7
<151> 2019-01-15
<160> 25
<170> PatentIn version 3.5
<210> 1
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 1
Cys Tyr Trp Asn Pro Phe Met Gly Cys Tyr Thr Cys
1 5 10
<210> 2
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 2
Cys Tyr Trp Asn Pro Phe Thr Gly Cys Tyr Ser Cys
1 5 10
<210> 3
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 3
Cys Tyr Trp Asn Pro Phe Ile Gln Cys Ser Pro Cys
1 5 10
<210> 4
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 4
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Tyr Met Cys
1 5 10
<210> 5
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 5
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Tyr Thr Cys
1 5 10
<210> 6
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 6
Cys Tyr Trp Asn Pro Phe Ala Ala Cys Tyr Asp Cys
1 5 10
<210> 7
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 7
Cys Tyr Trp Asn Pro Phe Ser Gly Cys Tyr Ser Cys
1 5 10
<210> 8
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 8
Cys Met Trp Asn Pro Phe Thr Gly Cys Tyr Ala Cys
1 5 10
<210> 9
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 9
Cys Leu Tyr Asn Pro Phe Thr Gly Cys Tyr Asp Cys
1 5 10
<210> 10
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 10
Cys Tyr Trp Asn Pro Phe Ser Gly Cys Trp Asp Cys
1 5 10
<210> 11
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 11
Cys Tyr Trp Asn Pro Phe Met Ala Cys Phe Asp Cys
1 5 10
<210> 12
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 12
Cys Tyr Trp Asn Pro Phe Met Gly Cys Tyr Ser Cys
1 5 10
<210> 13
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 13
Cys Tyr Trp Asn Pro Phe Met Ala Cys Tyr Val Cys
1 5 10
<210> 14
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 14
Cys Tyr Trp Asn Pro Phe Met Gly Cys Tyr Val Cys
1 5 10
<210> 15
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 15
Cys Tyr Trp Asn Pro Phe Thr Gly Cys Tyr Ala Cys
1 5 10
<210> 16
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 16
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Trp Ser Cys
1 5 10
<210> 17
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 17
Cys Phe Trp Asn Pro Phe Thr Gly Cys Tyr Ser Cys
1 5 10
<210> 18
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 18
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Phe Ser Cys
1 5 10
<210> 19
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 19
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Tyr Val Cys
1 5 10
<210> 20
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 20
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Tyr Ser Cys
1 5 10
<210> 21
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 21
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Trp Ala Cys
1 5 10
<210> 22
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 22
Cys Tyr Trp Asn Pro Phe Thr Ala Cys Phe Ala Cys
1 5 10
<210> 23
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa代表任何氨基酸残基
<220>
<221> Xaa
<222> (3)..(3)
<223> Xaa是W或Y
<220>
<221> Xaa
<222> (7)..(8)
<223> Xaa代表任何氨基酸残基
<220>
<221> Xaa
<222> (10)..(11)
<223> Xaa代表任何氨基酸残基
<400> 23
Cys Xaa Xaa Asn Pro Phe Xaa Xaa Cys Xaa Xaa Cys
1 5 10
<210> 24
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa代表任何氨基酸残基
<220>
<221> Xaa
<222> (7)..(8)
<223> Xaa代表任何氨基酸残基
<220>
<221> Xaa
<222> (10)..(11)
<223> Xaa代表任何氨基酸残基
<400> 24
Cys Xaa Trp Asn Pro Phe Xaa Xaa Cys Xaa Xaa Cys
1 5 10
<210> 25
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成肽
<400> 25
Ala Cys Tyr Trp Asn Pro Phe Thr Gly Cys Tyr Thr Cys Ala
1 5 10
Claims (12)
1.一种CD38特异性的肽配体,其包含多肽和非芳香族分子支架,所述多肽含有被至少两个环序列隔开的至少三个半胱氨酸残基,以及所述非芳香族分子支架与所述多肽的半胱氨酸残基形成共价键,从而在所述分子支架上形成至少两个多肽环。
2.根据权利要求1所限定的肽配体,其中所述环序列包含2或7个氨基酸。
3.根据权利要求1或权利要求2所限定的肽配体,其包含选自以下的氨基酸序列:
Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23);
或其药学上可接受的盐,其中X1-X5代表任何氨基酸残基,以及Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基。
4.根据权利要求1至3中任一项所限定的肽配体,其中所述环序列包含被两个环序列隔开的三个半胱氨酸残基,所述两个环序列中的第一个由7个氨基酸组成,而所述两个环序列中的第二个由2个氨基酸组成,并且所述肽配体包含选自以下的氨基酸序列:
Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23);
或其药学上可接受的盐,其中X1-X5代表任何氨基酸残基,以及Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基。
5.根据权利要求3或权利要求4所限定的肽配体,其中Ci-X1-W/Y-N-P-F-X2-X3-Cii-X4-X5-Ciii(SEQ ID NO:23)的肽配体包含选自SEQ ID NO:1-22中任一项的氨基酸序列:
CiYWNPFMGCiiYTCiii(SEQ ID NO:1);
CiYWNPFTGCiiYSCiii(SEQ ID NO:2);
CiYWNPFIQCiiSPCiii(SEQ ID NO:3);
CiYWNPFTACiiYMCiii(SEQ ID NO:4);
CiYWNPFTACiiYTCiii(SEQ ID NO:5);
CiYWNPFAACiiYDCiii(SEQ ID NO:6);
CiYWNPFSGCiiYSCiii(SEQ ID NO:7);
CiMWNPFTGCiiYACiii(SEQ ID NO:8);
CiLYNPFTGCiiYDCiii(SEQ ID NO:9);
CiYWNPFSGCiiWDCiii(SEQ ID NO:10);
CiYWNPFMACiiFDCiii(SEQ ID NO:11);
CiYWNPFMGCiiYSCiii(SEQ ID NO:12);
CiYWNPFMACiiYVCiii(SEQ ID NO:13);
CiYWNPFMGCiiYVCiii(SEQ ID NO:14);
CiYWNPFTGCiiYACiii(SEQ ID NO:15);
CiYWNPFTACiiWSCiii(SEQ ID NO:16);
CiFWNPFTGCiiYSCiii(SEQ ID NO:17);
CiYWNPFTACiiFSCiii(SEQ ID NO:18);
CiYWNPFTACiiYVCiii(SEQ ID NO:19);
CiYWNPFTACiiYSCiii(SEQ ID NO:20);
CiYWNPFTACiiWACiii(SEQ ID NO:21);以及
CiYWNPFTACiiFACiii(SEQ ID NO:22);
或其药学上可接受的盐;其中Ci、Cii和Ciii分别代表第一、第二和第三半胱氨酸残基,
例如:
选自以下的氨基酸序列:
A-(SEQ ID NO:1)-A(本文称为66-50-01-N001);
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:3)-A(本文称为66-50-03-N001);
A-(SEQ ID NO:4)-A(本文称为66-50-04-N001);
A-(SEQ ID NO:5)-A(本文称为66-50-05-N001);
A-(SEQ ID NO:6)-A(本文称为66-50-06-N001);
A-(SEQ ID NO:7)-A(本文称为66-50-07-N001);
A-(SEQ ID NO:8)-A(本文称为66-50-08-N001);
A-(SEQ ID NO:9)-A(本文称为66-50-09-N001);
A-(SEQ ID NO:10)-A(本文称为66-50-10-N001);
A-(SEQ ID NO:11)-A(本文称为66-50-11-N001);
A-(SEQ ID NO:12)-A(本文称为66-50-12-N001);
A-(SEQ ID NO:13)-A(本文称为66-50-13-N001);
A-(SEQ ID NO:14)-A(本文称为66-50-14-N001);
A-(SEQ ID NO:15)-DST(本文称为66-50-15-T01-N001);
A-(SEQ ID NO:15)-EAD(本文称为66-50-15-T02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:16)-DTS(本文称为66-50-22-T01-N001);
ASDN-(SEQ ID NO:17)-A(本文称为66-50-17-T01-N001);
ARNE-(SEQ ID NO:17)-A(本文称为66-50-17-T02-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);
A-(SEQ ID NO:19)-DVP(本文称为66-50-19-T01-N001);
A-(SEQ ID NO:20)-TEN(本文称为66-50-19-T02-N001);
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001);
A-(SEQ ID NO:22)-EEP(本文称为66-50-21-T01-N001);以及。
6.根据权利要求1所限定的肽配体,其中所述分子支架选自1,1',1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA),以及所述肽配体包含选自以下的氨基酸序列:
A-(SEQ ID NO:1)-A(本文称为66-50-01-N001);
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:3)-A(本文称为66-50-03-N001);
A-(SEQ ID NO:4)-A(本文称为66-50-04-N001);
A-(SEQ ID NO:5)-A(本文称为66-50-05-N001);
A-(SEQ ID NO:6)-A(本文称为66-50-06-N001);
A-(SEQ ID NO:7)-A(本文称为66-50-07-N001);
A-(SEQ ID NO:8)-A(本文称为66-50-08-N001);
A-(SEQ ID NO:9)-A(本文称为66-50-09-N001);
A-(SEQ ID NO:10)-A(本文称为66-50-10-N001);
A-(SEQ ID NO:11)-A(本文称为66-50-11-N001);
A-(SEQ ID NO:12)-A(本文称为66-50-12-N001);
A-(SEQ ID NO:13)-A(本文称为66-50-13-N001);
A-(SEQ ID NO:14)-A(本文称为66-50-14-N001);
A-(SEQ ID NO:15)-DST(本文称为66-50-15-T01-N001);
A-(SEQ ID NO:15)-EAD(本文称为66-50-15-T02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:16)-DTS(本文称为66-50-22-T01-N001);
ASDN-(SEQ ID NO:17)-A(本文称为66-50-17-T01-N001);
ARNE-(SEQ ID NO:17)-A(本文称为66-50-17-T02-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);
A-(SEQ ID NO:19)-DVP(本文称为66-50-19-T01-N001);
A-(SEQ ID NO:20)-TEN(本文称为66-50-19-T02-N001);
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001);
A-(SEQ ID NO:22)-EEP(本文称为66-50-21-T01-N001);以及
例如:
选自以下的氨基酸序列:
A-(SEQ ID NO:2)-A(本文称为66-50-02-N001);
A-(SEQ ID NO:16)-END(本文称为66-50-16-T01-N001);
A-(SEQ ID NO:18)-FSCDDD(本文称为66-50-18-T01-N001);以及
A-(SEQ ID NO:21)-EPD(本文称为66-50-20-T01-N001)。
7.根据权利要求1至6中任一项所限定的肽配体,其中所述药学上可接受的盐选自游离酸或钠、钾、钙、铵盐。
8.根据权利要求1至7中任一项所限定的肽配体,其中所述CD38是人CD38。
9.一种药物缀合物,其包含根据权利要求1至8中任一项所限定的肽配体,所述肽配体与一个或多个效应物和/或官能团缀合。
10.一种药物缀合物,其包含根据权利要求1至8中任一项所限定的肽配体,所述肽配体与一个或多个细胞毒性剂缀合。
11.一种药物组合物,其包含与一种或多种药学上可接受的赋形剂组合的权利要求1至8中任一项所限定的肽配体、或权利要求9或权利要求10所限定的药物缀合物。
12.权利要求1至8中任一项所限定的肽配体或权利要求9或权利要求10所限定的药物缀合物在预防、抑制或治疗CD38介导的疾病或病症中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1900529.7A GB201900529D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for CD38 |
GB1900529.7 | 2019-01-15 | ||
PCT/GB2020/050073 WO2020148529A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for cd38 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113543813A true CN113543813A (zh) | 2021-10-22 |
CN113543813B CN113543813B (zh) | 2024-03-29 |
Family
ID=65528180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080019655.7A Active CN113543813B (zh) | 2019-01-15 | 2020-01-15 | Cd38特异性的双环肽配体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220064218A1 (zh) |
EP (1) | EP3911365A1 (zh) |
JP (1) | JP2022517040A (zh) |
CN (1) | CN113543813B (zh) |
GB (1) | GB201900529D0 (zh) |
WO (1) | WO2020148529A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020529427A (ja) | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100317547A1 (en) * | 2008-02-05 | 2010-12-16 | Medical Research Council | Methods and compositions |
CN105189747A (zh) * | 2013-03-15 | 2015-12-23 | 拜斯科医疗有限公司 | 多肽的修饰 |
EP3192801A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Peptides derivatives |
EP3192802A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Stabilized peptide derivatives |
US20180371020A1 (en) * | 2017-06-26 | 2018-12-27 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2541489T3 (es) | 2004-02-06 | 2015-07-21 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
DK3215518T3 (da) | 2014-10-29 | 2021-05-25 | Bicyclerd Ltd | Bicykliske peptidligander, der er specifikke for mt1-mmp |
GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
-
2019
- 2019-01-15 GB GBGB1900529.7A patent/GB201900529D0/en not_active Ceased
-
2020
- 2020-01-15 US US17/422,940 patent/US20220064218A1/en active Pending
- 2020-01-15 JP JP2021540842A patent/JP2022517040A/ja active Pending
- 2020-01-15 WO PCT/GB2020/050073 patent/WO2020148529A1/en unknown
- 2020-01-15 CN CN202080019655.7A patent/CN113543813B/zh active Active
- 2020-01-15 EP EP20701837.5A patent/EP3911365A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100317547A1 (en) * | 2008-02-05 | 2010-12-16 | Medical Research Council | Methods and compositions |
CN105189747A (zh) * | 2013-03-15 | 2015-12-23 | 拜斯科医疗有限公司 | 多肽的修饰 |
EP3192801A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Peptides derivatives |
EP3192802A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Stabilized peptide derivatives |
US20180371020A1 (en) * | 2017-06-26 | 2018-12-27 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
Non-Patent Citations (2)
Title |
---|
CURRAN A. RHODES AND DEHUA PEI: "Bicyclic Peptides as Next-Generation Therapeutics", 《CHEM. EUR. J》, pages 12690 - 12703 * |
SHIYU CHEN等: "Peptide Ligands Stabilized by Small Molecules", 《ANGEW. CHEM》, pages 1628 - 1632 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022517040A (ja) | 2022-03-03 |
GB201900529D0 (en) | 2019-03-06 |
CN113543813B (zh) | 2024-03-29 |
EP3911365A1 (en) | 2021-11-24 |
WO2020148529A1 (en) | 2020-07-23 |
US20220064218A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111183147B (zh) | Cd137特异性的双环肽配体 | |
US11306123B2 (en) | Heterotandem bicyclic peptide complex | |
JP2024023291A (ja) | 多量体二環式ペプチドリガンド | |
CN111741771A (zh) | 特异于epha2的双环肽配体 | |
JP2023175683A (ja) | EphA2に特異的な二環ペプチドリガンド | |
CN114867753A (zh) | 异串联双环肽复合物 | |
CN113474045A (zh) | Pd-l1特异性的双环肽配体 | |
CN113474046A (zh) | Il-17特异性的双环肽配体 | |
CN113507960A (zh) | Psma特异性的双环肽配体 | |
CN113383074A (zh) | Caix特异性的双环肽配体 | |
CN112533937A (zh) | 用于结合cd38的肽配体 | |
CN113260420A (zh) | Pd-l1特异性的双环肽配体 | |
CN113613728A (zh) | 整联蛋白αvβ3特异性的双环肽配体 | |
CN113597317A (zh) | Cd38特异性的双环肽配体 | |
CN113383007A (zh) | Caix特异性的双环肽配体 | |
CN113507961A (zh) | FAPα特异性的双环肽配体 | |
CN113543813B (zh) | Cd38特异性的双环肽配体 | |
CN113439088A (zh) | 整联蛋白αvβ3特异性的双环肽配体 | |
CN114787177A (zh) | Il-17特异性的双环肽配体 | |
CN114829376A (zh) | Il-17特异性的双环肽配体 | |
CN114867736A (zh) | Il-17特异性的双环肽配体 | |
CN114787176A (zh) | Il-17特异性的双环肽配体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |